Related Experiment Video

Updated: Aug 8, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

The current status of interferon alpha in haemic malignancy

D W Galvani1, J C Cawley

  • 1University Department of Haematology, Royal Liverpool Hospital, UK.

Blood Reviews
|September 1, 1990
PubMed

Insights

Interferon-alpha (IFN alpha) is effective in treating specific blood cancers like hairy cell and chronic granulocytic leukemia. This review discusses its current use and the reasons for its sensitivity in these conditions.

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Interferon-alpha (IFN alpha) is a cytokine with established therapeutic applications.
  • Its efficacy has been most pronounced in hematologic malignancies.
  • Extensive research has been conducted on IFN alpha in both clinical and laboratory settings.

Purpose of the Study:

  • To review the current status of Interferon-alpha (IFN alpha) in treating specific hematologic malignancies.
  • To explore the underlying mechanisms contributing to the sensitivity of these cancers to IFN alpha.
  • To discuss the role of IFN alpha in less responsive hematologic malignancies.

Main Methods:

  • Literature review of clinical trials and laboratory studies on Interferon-alpha (IFN alpha).
  • Analysis of data on treatment responses in various hematologic malignancies.
  • Exploration of biological mechanisms of IFN alpha action and sensitivity.

Main Results:

  • Interferon-alpha (IFN alpha) demonstrates significant effectiveness in hairy cell leukemia and chronic granulocytic leukemia.
  • The sensitivity of these specific leukemias to IFN alpha is linked to particular biological factors.
  • Limited responsiveness is observed in other hematologic malignancies.

Conclusions:

  • Interferon-alpha (IFN alpha) remains a key therapeutic agent for certain hematologic cancers.
  • Understanding the basis of sensitivity can guide future treatment strategies.
  • Further research is warranted for optimizing IFN alpha use in broader hematologic malignancies.

More Related Videos

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...